Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Tesamorelin (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 27 Nov 2019 According to an Theratechnologies media release, the company announced that Philippe Dubuc, the company's CFO will attend the Piper Jaffray 31st Annual Healthcare and will hold several meetings with representatives from various investment firms to discuss the latest developments announced by the company including the publication of clinical trial results in the Lancet HIV.
- 14 Oct 2019 Results presented in a Theratechnologies media release.
- 11 Oct 2019 Results presened in a Theratechnologies Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History